---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-118973"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:49:44.774894+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns

## Summary
- Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.
- Gross profit -$1.7M (Q3 2021: $1.8M); SG&A reduced to $2.2M from $3.4M on cost-cutting.
- Net loss widened to $13.8M from $1.7M; cash $11.2M vs $13.3M prior quarter.
- FDA approved label expansion for STENDRA (avanafil) for ED in men post-radical prostatectomy.
- Company shifts primary focus to over-the-counter access for STENDRA, citing improved shelf life.

## SEC filing metadata
- accession: 0001104659-22-118973
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/0001104659-22-118973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/tm2230572d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-118973
- JSON: https://secwatch.observer/filing/0001104659-22-118973.json
- Plain text: https://secwatch.observer/filing/0001104659-22-118973.txt

## Key facts
- Earnings Releases
  Petros Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue negative $1.4 million, net income $13.8 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: negative $1.4 million
  - Net income: $13.8 million
  - Result: reported results
  source text: and will manage cash prudently to achieve that goal,” concluded Mr. Boctor. Q3 2022 Financial Results Net sales for the third quarter ended September 30, 2022, were negative $1.4 million, comprised of negative $2.1 million of net sales from Prescription Medicines and $0.7 million of net sales from Medical Devices. This compares to net sales for the quarter ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815903/000110465922118973/0001104659-22-118973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.